[go: up one dir, main page]

WO2004080375A3 - Vaccine therapy of atherosclerosis - Google Patents

Vaccine therapy of atherosclerosis Download PDF

Info

Publication number
WO2004080375A3
WO2004080375A3 PCT/EP2004/002643 EP2004002643W WO2004080375A3 WO 2004080375 A3 WO2004080375 A3 WO 2004080375A3 EP 2004002643 W EP2004002643 W EP 2004002643W WO 2004080375 A3 WO2004080375 A3 WO 2004080375A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogens
apociii
atherosclerosis
present
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/002643
Other languages
French (fr)
Other versions
WO2004080375A2 (en
Inventor
Rene Meykens
Pascal Mettens
Philippe Monteyne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of WO2004080375A2 publication Critical patent/WO2004080375A2/en
Publication of WO2004080375A3 publication Critical patent/WO2004080375A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to novel vaccine therapies, and prophylactic treatments of atherosclerotic diseases. Accordingly there is provided, immunogens comprising specific fragments or derivatives of Apolipoprotein C-III (ApoCIII). The vaccines of the present invention, comprising said immunogens, are potent in the prevention, or reduction, of atherosclerotic plaque formation over prolonged periods of time, thereby reducing the potential of atherosclerosis leading to coronary or cerebrovascular disease. Also provided are methods of treating or preventing atherosclerosis by active vaccination, or passive vaccination through administration to a patient of an antibody that is capable of binding to the specific fragments of ApoCIII. Specific monoclonal antibodies and their use in therapy of atherosclerosis is provided. There is further provided the use of the immunogens of the present invention in medicine, and methods of their production. The fragments of ApoCIII which form the basis of the immunogens of the present invention, and also the targets for passive immunotherapy, are encompassed within the regions between amino acid numbers 45-76 and, particularly, 12-35 of the mature form of human ApoCIII.
PCT/EP2004/002643 2003-03-13 2004-03-11 Vaccine therapy of atherosclerosis Ceased WO2004080375A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0305794.0 2003-03-13
GBGB0305794.0A GB0305794D0 (en) 2003-03-13 2003-03-13 Vaccine

Publications (2)

Publication Number Publication Date
WO2004080375A2 WO2004080375A2 (en) 2004-09-23
WO2004080375A3 true WO2004080375A3 (en) 2005-01-13

Family

ID=9954733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/002643 Ceased WO2004080375A2 (en) 2003-03-13 2004-03-11 Vaccine therapy of atherosclerosis

Country Status (2)

Country Link
GB (1) GB0305794D0 (en)
WO (1) WO2004080375A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23736A1 (en) 2009-05-04 2011-11-15 Centro Inmunologia Molecular ANTIBODIES RECOGNIZING SULFATIDES AND SULFATED PROTEOGLYCANS AND THEIR USE
MA45602A (en) * 2016-07-08 2019-05-15 Staten Biotechnology B V ANTI-APOC3 ANTIBODIES AND THEIR METHODS OF USE
JP2020517242A (en) * 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー Anti-ApoC3 antibody and method of using the same
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
JP7039694B2 (en) 2017-10-31 2022-03-22 スターテン・バイオテクノロジー・ベー・フェー Anti-APOC3 antibody and how to use it
US11690901B2 (en) 2020-03-03 2023-07-04 The United States Of America, As Represented By The Secretary Of Agriculture Southern cattle tick vaccine product
WO2022136466A1 (en) 2020-12-23 2022-06-30 Argonaute RNA Limited Treatment of cardiovascular disease
JP2024531728A (en) 2021-09-14 2024-08-29 アルゴノート アールエヌエー リミテッド Treatment of Cardiovascular Disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378881A1 (en) * 1989-01-17 1990-07-25 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
WO2001064008A2 (en) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccine for the treatment of artherosclerosis
WO2003020765A2 (en) * 2001-08-31 2003-03-13 Glaxosmithkline Biologicals S.A. Vaccine therapies and prophylactic treatments of atherosclerotic diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378881A1 (en) * 1989-01-17 1990-07-25 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
WO2001064008A2 (en) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccine for the treatment of artherosclerosis
WO2003020765A2 (en) * 2001-08-31 2003-03-13 Glaxosmithkline Biologicals S.A. Vaccine therapies and prophylactic treatments of atherosclerotic diseases

Also Published As

Publication number Publication date
GB0305794D0 (en) 2003-04-16
WO2004080375A2 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
WO2003020765A3 (en) Vaccine therapies and prophylactic treatments of atherosclerotic diseases
WO2001064008A3 (en) Vaccine for the treatment of artherosclerosis
WO2003090686A3 (en) Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2002034205A3 (en) Using heat shock proteins to increase immune response
HUP0303173A2 (en) Modified anti-egfr antibodies with reduced immunogenicity
WO2002056905A3 (en) Molecular antigen array
JP2004501101A5 (en)
WO2005063201A3 (en) Liposomes and liposomal compositions for vaccination and drug delivery
BRPI0610093A2 (en) pharmaceutical composition, and method for preventing or treating a disease associated with alpha-beta amyloid deposits in a patient's brain
BRPI0010612B8 (en) vaccines
WO2010067286A3 (en) IgE CH3 PEPTIDE VACCINE
JP2006506441A5 (en)
WO2010016912A3 (en) Immunotherapeutic compositions for the treatment of alzheimer's disease
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
WO2004080375A3 (en) Vaccine therapy of atherosclerosis
WO2003059385A3 (en) Hiv vaccine and method of use
WO2004081045A3 (en) Vaccine related to modified apolipoprotein c-iii
WO2003090687A8 (en) Using heat shock proteins to increase immune response
AU2003263712A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2002060435A8 (en) Cryptotanshinone for preventing and alleviating alzheimer's disease
Pfützner et al. AIT: new avenues in allergen immunotherapy
WO2004081046A3 (en) Human monoclonal antibodies against apociii and their use in the therapy of atherosclerosis
EP2359850A1 (en) Single-time vaccines
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
CN101595126A (en) Use of a first house dust mite group 2 allergen for the treatment of allergy to a second house dust mite group 2 allergen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase